Last reviewed · How we verify
G207
At a glance
| Generic name | G207 |
|---|---|
| Also known as | HSV G207 |
| Sponsor | Gregory K. Friedman, MD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (PHASE1)
- HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma (PHASE2)
- HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors (PHASE1)
- G207 Followed by Radiation Therapy in Malignant Glioma (PHASE1)
- Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- G207 CI brief — competitive landscape report
- G207 updates RSS · CI watch RSS
- Gregory K. Friedman, MD portfolio CI